Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.

Julien Grynblat Charles KhouriAlex HlavatyXavier Jais Laurent Savale Marie-Camille Chaumais Mithum Kularatne Mitja Jevnikar Athénaïs Boucly Fabrice Antigny Frédéric PerrosGérald SimonneauOlivier Sitbon Marc Humbert I David Montaninull null

Published in: The European respiratory journal (2024)

PIs may induce PAH in patients undergoing treatment, with carfilzomib emitting a stronger signal than bortezomib, and these patients should be monitored closely.

Keyphrases

end stage renal disease
newly diagnosed
pulmonary hypertension
patients undergoing
ejection fraction
chronic kidney disease
peritoneal dialysis
metabolic syndrome
pulmonary arterial hypertension
weight loss
insulin resistance
skeletal muscle
replacement therapy
smoking cessation